High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults.
Since the early 1980s high dose chemotherapy with autologous hematopoietic stem cell support was adopted by many oncologists as a potentially curative option for solid tumors, supported by a strong rationale from laboratory studies and apparently convincing results of early phase II studies. As a result, the number and size of randomized trials comparing this approach with conventional chemotherapy initiated (and often abandoned before completion) to prove or disprove its value was largely insufficient. In fact, with the possible exception of breast carcinoma, the benefit of a greater escalation of dose of chemotherapy with stem cell support in solid tumors is still unsettled and many oncologists believe that this approach should cease. In this article, we critically review and comment on the data from studies of high dose chemotherapy so far reported in adult patients with small cell lung cancer, ovarian cancer, germ cell tumors and sarcomas.
Falck Division of Medical Oncology, Ospedale Niguarda Ca' Granda, Milano, Italy. paolo.pedrazzoli@ospedaleniguarda.it
P
P
Pedrazzoli
J A
JA
Ledermann
J-P
JP
Lotz
S
S
Leyvraz
M
M
Aglietta
G
G
Rosti
K M
KM
Champion
S
S
Secondino
F
F
Selle
N
N
Ketterer
G
G
Grignani
S
S
Siena
T
T
Demirer
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000628:therapy; D018288:Carcinoma, Small Cell / Q000628:therapy; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery*; D009373:Neoplasms, Germ Cell and Embryonal / Q000628:therapy; D010051:Ovarian Neoplasms / Q000628:therapy; D011379:Prognosis; D016879:Salvage Therapy; D012509:Sarcoma / Q000628:therapy
D000970:Antineoplastic Agents